Cefepime Drug Information
Generic name: CEFEPIME
Uses of Cefepime
Pneumonia Cefepime for Injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.
Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients.
Uncomplicated and Complicated Urinary Tract
Infections (including pyelonephritis) Cefepime for Injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these bacteria.
Uncomplicated Skin and Skin Structure Infections Cefepime for Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
Complicated Intra-abdominal
Infections (used in combination with metronidazole) Cefepime for Injection is indicated in the treatment of complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible isolates of Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Dosage & Administration of Cefepime
Dosage for Adults
The recommended adult dosages and routes of administration are outlined in Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer Cefepime for Injection intravenously over approximately 30 minutes. Table 1: Recommended Dosage Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/min
Pediatric Patients (2 months up to 16 years)
The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for durations as given above for adults is: •50 mg per kg per dose, administered every 12 hours for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia (see below).•For moderate to severe pneumonia due to P. aeruginosa give 50 mg per kg per dose, every 8 hours.•50 mg per kg per dose, every 8 hours for febrile neutropenic patients.
Dosage Adjustments in Patients with Renal Impairment Adult Patients Adjust the dose of Cefepime for Injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of Cefepime for Injection should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis. The recommended doses of Cefepime for Injection in patients with renal impairment are presented in Table 2.
When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of re Table 2: Recommended Dosing Schedule for Cefepime for Injection in Adult Patients With Creatinine Clearance Less Than or Equal to 60 mL/min, Cefepime for Injection may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2 ). In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period.
Cefepime for Injection should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2 ). Pediatric Patients Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients, changes in the dosing regimen proportional to those in adults (see Tables 1 and 2 ) are recommended for pediatric patients.
Preparation of Cefepime for Injection for Intravenous Infusion •Constitute the 0.5 gram, 1 gram, or 2 grams vial, of Cefepime for Injection with the one of the following diluents: o Sterile Water for Injection o 0.9% Sodium Chloride Injection o 5% Dextrose Injection o 0.5% or 1% Lidocaine Hydrochloride Injection o Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol •Dilute the reconstituted solution with one of the following compatible infusion solutions prior to intravenous infusion (Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of the reconstituted solution to be withdrawn): o 0.9% Sodium Chloride Injection o 5% and 10% Dextrose Injection o M/6 Sodium Lactate Injection o 5% Dextrose and 0.9% sodium Chloride Injection o Lactated Rings and 5% Dextrose Injection o Normosol ® -R and Normosol ® -M in 5% Dextrose Injection •Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. •Administer the resulting intravenous infusion over approximately 30 minutes. •Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing cefepime, it is desirable to discontinue the other solution.
These solutions may be stored up to 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F). Admixture Compatibility Cefepime for Injection admixture compatibility information is summarized in Table 4. Table 4: Cefepime Admixture Stability Cefepime for Injection Admixture Incompatibility Do not add solutions of Cefepime for Injection, to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction.
However, if concurrent therapy with Cefepime for Injection is indicated, each of these antibacterial drugs can be administered separately. Intramuscular Cefepime for Injection Cefepime for Injection constituted as directed is stable for 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or for 7 days in a refrigerator 2°C to 8°C (36°F to 46°F) with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5% or 1% Lidocaine Hydrochloride. Intramuscular and Intravenous Cefepime for Injection As with other cephalosporins, the color of Cefepime for Injection powder, as well as its solutions tend to darken depending on storage conditions; however, when stored as recommended, the product potency is not adversely affected.
| § For Pseudomonas aeruginosa, use 2 g IV every 8 hours. ( 2.1 ) *Or until resolution of neutropenia. ( 2.1 ) *Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli. ( 2.1 ) | |||
| Recommended Dosage in Adults with Creatinine Clearance (CrCL) Greater Than 60 mL/min ( 2.1 ) | |||
| Site and Type of Infection | Dose | Frequency | Duration (days) |
| Moderate to Severe Pneumonia § | 1-2 g IV | Every 8-12 hours | 10 |
| Empiric Therapy for Febrile Neutropenic Patients | 2 g IV | Every 8 hours | 7* |
| Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections | 0.5-1 g IV/IM* | Every 12 hours | 7-10 |
| Severe Uncomplicated or Complicated Urinary Tract Infections | 2 g IV | Every 12 hours | 10 |
| Moderate to Severe Uncomplicated Skin and Skin Structure Infections | 2 g IV | Every 12 hours | 10 |
| Complicated Intra-abdominal Infections § (used in combination with metronidazole) | 2 g IV | Every 12 hours | 7-10 |
| *or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. *Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli. § For P. aeruginosa, use 2 g IV every 8 hours. | |||
| Site and Type of Infection | Dose | Frequency | Duration |
| (days) | |||
| Adults | Intravenous (IV)/Intramuscular (IM) | ||
| Moderate to Severe Pneumonia § | 1 to 2 g IV | Every 8 to 12 hours | 10 |
| Empiric therapy for febrile neutropenic patients | 2 g IV | Every 8 hours | 7* |
| Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis | 0.5 to 1 g IV/IM* | Every 12 hours | 7 to 10 |
| Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis | 2 g IV | Every 12 hours | 10 |
| Moderate to Severe Uncomplicated Skin and Skin Structure Infections | 2 g IV | Every 12 hours | 10 |
| Complicated Intra-abdominal Infections § (used in combination with metronidazole) | 2 g IV | Every 8 to 12 hours | 7 to 10 |
| Males: Creatinine Clearance (mL/min) = | Weight (kg) x (140 – age) |
| 72 × serum creatinine (mg/dL) | |
| Females: 0.85 × above value | |
| Creatinine Clearance (mL/min) | Recommended Maintenance Schedule | |||
|---|---|---|---|---|
| Greater than 60 | 500 mg every 12 hours | 1 g every 12 hours | 2 g every 12 hours | 2 g every 8 hours |
| 30 to 60 | 500 mg every 24 hours | 1 g every 24 hours | 2 g every 24 hours | 2 g every 12 hours |
| 11 to 29 | 500 mg every 24 hours | 500 mg every 24 hours | 1 g every 24 hours | 2 g every 24 hours |
| Less than 11 | 250 mg every 24 hours | 250 mg every 24 hours | 500 mg every 24 hours | 1 g every 24 hours |
| Continuous Ambulatory Peritoneal Dialysis (CAPD) | 500 mg every 48 hours | 1 g every 48 hours | 2 g every 48 hours | 2 g every 48 hours |
| Hemodialysis On hemodialysis days, cefepime should be administered following hemodialysis. Whenever possible, cefepime should be administered at the same time each day. | 1 g on day 1, then 500 mg every 24 hours thereafter | 1 g every 24 hours | ||
| Single-Dose Vials for Intravenous (IV)/Intramuscular (IM)Administration | Amount of Diluent to be added (mL) | Approximate Cefepime Concentration (mg/mL) | Amount of Reconstituted Volume to be Withdrawn (mL) |
|---|---|---|---|
| 500 mg (IV) | 5 | 100 | 5 |
| 500 mg (IM) | 1.3 | 280 | 1.8 |
| 1 g (IV) | 10 | 100 | 10.5 |
| 1 g (IM) | 2.4 | 280 | 3.6 |
| 2 g (IV) | 10 | 160 | 12.5 |
| NS = 0.9% Sodium Chloride Injection. D5W = 5% Dextrose Injection. na = not applicable. RT/L = Ambient room temperature and light. | ||||
| Stability Time for | ||||
| Cefepime for Injection Concentration | Admixture and Concentration | Intravenous (IV) Infusion Solutions | RT/L (20° to 25°C) | Refrigeration (2° to 8°C) |
| 40 mg/mL | Amikacin 6 mg/mL | NS or D5W | 24 hours | 7 days |
| 40 mg/mL | Ampicillin 1 mg/mL | D5W | 8 hours | 8 hours |
| 40 mg/mL | Ampicillin 10 mg/mL | D5W | 2 hours | 8 hours |
| 40 mg/mL | Ampicillin 1 mg/mL | NS | 24 hours | 48 hours |
| 40 mg/mL | Ampicillin 10 mg/mL | NS | 8 hours | 48 hours |
| 4 mg/mL | Ampicillin 40 mg/mL | NS | 8 hours | 8 hours |
| 4 to 40 mg/mL | Clindamycin Phosphate 0.25 to 6 mg/mL | NS or D5W | 24 hours | 7 days |
| 4 mg/mL | Heparin 10 to 50 units/mL | NS or D5W | 24 hours | 7 days |
| 4 mg/mL | Potassium Chloride 10 to 40 mEq/L | NS or D5W | 24 hours | 7 days |
| 4 mg/mL | Theophylline 0.8 mg/mL | D5W | 24 hours | 7 days |
| 1 to 4 mg/mL | na | Aminosyn™ II 4.25% with electrolytes and calcium | 8 hours | 3 days |
| 0.125 to 0.25 mg/mL | na | Inpersol™ with 4.25% dextrose | 24 hours | 7 days |
Side Effects of Cefepime
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. There were no deaths or permanent disabilities thought related to drug toxicity. Sixty-four (1.5%) patients discontinued medication due to adverse reactions.
Thirty-three (51%) of these 64 patients who discontinued therapy did so because of rash. However, the incidence of discontinuation due to rash increased with the higher recommended doses. The following adverse reactions ( Table 5 ) were identified in clinical trials conducted in North America (n=3125 cefepime-treated patients).
The following ( Table 6 ) adverse laboratory changes, with cefepime, were seen during clinical trials conducted in North America. Clinical consequences from changes in either calcium or phosphorus were not reported., hematocrit, neutrophils, platelets, White Blood Cells (WBC) A similar safety profile was seen in clinical trials of pediatric patients
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Cefepime for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. In addition to the adverse reactions reported during the North American clinical trials with cefepime, the following adverse reactions have been reported during worldwide postmarketing experience.
Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus have been reported. Anaphylaxis including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis and thrombocytopenia, have been reported.
Cephalosporin-Class Adverse Reactions
In addition to the adverse reactions listed above that have been observed in patients treated with cefepime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, hepatic dysfunction including cholestasis, and pancytopenia.
| Incidence equal to or greater than 1% | Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%); rash (1.1%) |
| Incidence less than 1% but greater than 0.1% | Colitis (including pseudomembranous colitis), diarrhea, erythema, fever, headache, nausea, oral moniliasis, pruritus, urticaria, vaginitis, vomiting, anemia |
| Incidence equal to or greater than 1% | Positive Coombs’ test (without hemolysis) (16.2%); decreased phosphorus (2.8%); increased Alanine Transaminase (ALT) (2.8%), Aspartate Transaminase (AST) (2.4%), eosinophils (1.7%); abnormal PTT (1.6%), Prothrombin Time (PT) (1.4%) |
| Incidence less than 1% but greater than 0.1% | Increased alkaline phosphatase, Blood Urea Nitrogen (BUN), calcium, creatinine, phosphorus, potassium, total bilirubin; decreased calcium Hypocalcemia was more common among elderly patients. Clinical consequences from changes in either calcium or phosphorus were not reported., hematocrit, neutrophils, platelets, White Blood Cells (WBC) |
Warnings & Cautions for Cefepime
Hypersensitivity Reactions
Before therapy with Cefepime for Injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefepime, cephalosporins, penicillins, or other beta-lactams. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefepime for Injection occurs, discontinue the drug and institute appropriate supportive measures.
Neurotoxicity
Serious adverse reactions have been reported including life-threatening or fatal occurrences of the following: encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus. Most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment. However, some cases of neurotoxicity occurred in patients receiving a dosage adjustment appropriate for their degree of renal impairment.
In the majority of cases, symptoms of neurotoxicity were reversible and resolved after discontinuation of cefepime and/or after hemodialysis. If neurotoxicity associated with cefepime therapy occurs, discontinue cefepime and institute appropriate supportive measures.
Clostridioides difficile -Associated Diarrhea
Clostridioides difficile -Associated Diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefepime for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD.
Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Development of Drug-Resistant Bacteria Prescribing Cefepime for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. As with other antimicrobials, prolonged use of Cefepime for Injection may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient’s condition is essential.
Should superinfection occur during therapy, appropriate measures should be taken.
Drug/Laboratory Test Interactions Urinary Glucose
The administration of cefepime may result in a false-positive reaction for glucose in the urine when using some methods (e.g. Clinitest™ tablets). Coombs’ Tests Positive direct Coombs’ tests have been reported during treatment with Cefepime for Injection.
In patients who develop hemolytic anemia, discontinue the drug and institute appropriate therapy. Positive Coombs’ test may be observed in newborns whose mothers have received cephalosporin antibacterial drugs before parturition. Prothrombin Time Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity.
Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated.
Drug Interactions with Cefepime
Drug/Laboratory Test Interactions
The administration of cefepime may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
Aminoglycosides
Monitor renal function if aminoglycosides are to be administered with Cefepime for Injection because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.
Diuretics Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function when cefepime is concomitantly administered with potent diuretics.
Pregnancy Safety for Cefepime
Pregnancy Risk Summary There are no cases of Cefepime for Injection exposure during pregnancy reported from postmarketing experience or from clinical trials. Available data from published observational studies and case reports over several decades with cephalosporin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes ( see Data ). Cefepime was not associated with adverse developmental outcomes in rats, mice, or rabbits when administered parenterally during organogenesis.
The doses used in these studies were 1.6 (rats), approximately equal to (mice), and 0.3 times (rabbits) the recommended maximum human dose ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is respectively. Data Human Data While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups.
Animal Data Cefepime was not embryocidal and did not cause fetal malformations when administered parenterally during the period of organogenesis to rats at doses up to 1000 mg/kg/day, to mice at doses up to 1200 mg/kg/day, or to rabbits at doses up to 100 mg/kg/day. These doses are 1.6 times (rats), approximately equal to (mice), and 0.3 times (rabbits) the maximum recommended clinical dose based on body surface area.
Pediatric Use of Cefepime
Pediatric Use The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 years. Use of Cefepime for Injection in these age groups is supported by evidence from adequate and well-controlled studies of cefepime in adults with additional pharmacokinetic and safety data from pediatric trials. Safety and effectiveness in pediatric patients below the age of 2 months have not been established.
There are insufficient clinical data to support the use of Cefepime for Injection in pediatric patients for the treatment of serious infections in the pediatric population where the suspected or proven pathogen is H. influenzae type b. In those patients in whom meningeal seeding from a distant infection site or in whom meningitis is suspected or documented, an alternate agent with demonstrated clinical efficacy in this setting should be used.
Contraindications for Cefepime
Cefepime for Injection is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibacterial drugs, penicillins or other beta-lactam antibacterial drugs. Patients with known immediate hypersensitivity reactions to cefepime or other cephalosporins, penicillins or other beta-lactam antibacterial drugs.
Overdosage Information for Cefepime
Patients who receive an overdose should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis, not peritoneal dialysis, is recommended to aid in the removal of cefepime from the body. Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, neuromuscular excitability and nonconvulsive status epilepticus.
Clinical Studies of Cefepime
Febrile Neutropenic Patients
The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials comparing cefepime monotherapy (at a dose of 2 g intravenously every 8 hours) to ceftazidime monotherapy (at a dose of 2 g intravenously every 8 hours). These studies comprised 317 evaluable patients. Table 10 describes the characteristics of the evaluable patient population.
Table 10: Demographics of Evaluable Patients (First Episodes Only) Table 11 describes the clinical response rates observed. For all outcome measures, cefepime was therapeutically equivalent to ceftazidime. Table 11: Pooled Response Rates for Empiric Therapy of Febrile Neutropenic Patients Insufficient data exist to support the efficacy of cefepime monotherapy in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia).
The study was designed to demonstrate equivalence of the two therapies. The primary analyses were conducted on the population consisting of those with a surgically confirmed complicated infection, at least one pathogen isolated pretreatment, at least 5 days of treatment, and a 4 to 6-week follow-up assessment for cured patients. Subjects in the imipenem/cilastatin arm had higher APACHE II scores at baseline.
The treatment groups were otherwise generally comparable with regard to their pretreatment characteristics. The observed differences in efficacy may have been due to a greater proportion of patients with high APACHE II scores in the imipenem/cilastatin group.
| ANC = absolute neutrophil count; SBP = systolic blood pressure | ||
| Cefepime | Ceftazidime | |
| Total | 164 | 153 |
| Median age (yr) | 56 (range, 18 to 82) | 55 (range, 16 to 84) |
| Male | 86 (52%) | 85 (56%) |
| Female | 78 (48%) | 68 (44%) |
| Leukemia | 65 (40%) | 52 (34%) |
| Other hematologic malignancies | 43 (26%) | 36 (24%) |
| Solid tumor | 54 (33%) | 56 (37%) |
| Median ANC nadir (cells/microliter) | 20 (range, 0 to 500) | 20 (range, 0 to 500) |
| Median duration of neutropenia (days) | 6 (range, 0 to 39) | 6 (range, 0 to 32) |
| Indwelling venous catheter | 97 (59%) | 86 (56%) |
| Prophylactic antibacterial drugs | 62 (38%) | 64 (42%) |
| Bone marrow graft | 9 (5%) | 7 (5%) |
| SBP less than 90 mm Hg at entry | 7 (4%) | 2 (1%) |
| % Response | ||
| Cefepime | Ceftazidime | |
| Outcome Measures | (n=164) | (n=153) |
| Primary episode resolved with no treatment modification, no new febrile episodes or infection, and oral antibacterial drugs allowed for completion of treatment | 51 | 55 |
| Primary episode resolved with no treatment modification, no new febrile episodes or infection and no post-treatment oral antibacterial drugs | 34 | 39 |
| Survival, any treatment modification allowed | 93 | 97 |
| Primary episode resolved with no treatment modification and oral antibacterial drugs allowed for completion of treatment | 62 | 67 |
| Primary episode resolved with no treatment modification and no post-treatment oral antibacterial drugs | 46 | 51 |
Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.
Ready to save on Cefepime?
Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.
Compare Cefepime Prices